Core Insights - Madrigal Pharmaceuticals, Inc. is focused on developing innovative therapies for cardiovascular and metabolic diseases, particularly in liver-related conditions like non-alcoholic steatohepatitis (NASH) [1] - Goldman Sachs has reiterated a "Buy" rating for Madrigal, indicating confidence in the company's growth potential despite a recent stock price decrease [2][5] Company Performance - The stock price of Madrigal Pharmaceuticals is approximately $493.90, reflecting a decrease of 3.26% or $16.63 from its previous value, indicating market volatility [2][5] - The company's market capitalization is around $10.95 billion, with a trading volume of 430,259 shares, showing significant interest in its stock [4] Recent Developments - Madrigal recently presented at the 44th Annual J.P. Morgan Healthcare Conference, providing insights into its latest developments and strategic direction in the NASH space [3][5] - The stock has fluctuated between $493.19 and $514.36 during the day, reflecting market responses to the company's updates [3]

Altimmune (ALT) Q2 2025 Earnings Call August 12, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. A reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McClellan, Investor Relations Adviser t ...